Mylan twarted by court in Topamax case

TITUSVILLE, N.J. The U.S. Court of Appeals for the Federal Circuit has upheld a ruling that prevents Mylan from marketing a generic version of Ortho-McNeil Pharmaceutical’s epilepsy drug Topamax, according to Reuters.

The decision was originally found in a District Court in New Jersey. Now, Mylan has to wait until the patent expires in September before launching a generic.

Topamax had sales in 2007 of over $1.8 billion.